HEMAB THERAPEUTICS HOLDINGS, INC.
COAGLoading price...
Overview
Previous Close44.53
Open44.50
Ask60.48
Bid35.57
Day's Range43.26 - 50.11
52 Week Range23.00 - 50.11
PE Ratio(TTM)--
Market Cap2.3B
Volume318.41k
Avg. Volume350.38k
12 Months Earnings-71.29M
12 Months Revenue0.00
Performance
ABSCAGR
| YTD | 1 Month | 3 Months | 1 Year | 2 Years | 5 Years | 10 Years | |
|---|---|---|---|---|---|---|---|
| No results to display | |||||||
Profit/Loss
| PARTICULARS | TTM | 2025 | 2024 |
|---|---|---|---|
| Operating Revenue | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 77.17M | 70.12M | 50.38M |
| Profit after Tax (Net Income) | -71.29M | -63.91M | -48.71M |
Company Profile
Sector: Healthcare
Industry: Biotechnology
HQ Location: Cambridge, United States
Website: https://www.hemab.com
President, CEO & Director: Dr. Benny Sorensen M.D., Ph.D.
Employees: 59
About Company:
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.